Synthesis, characterization, interaction with DNA and cytotoxicity of the new potential antitumour drug cis-K[Ru(eddp)Cl-2]
Само за регистроване кориснике
2003
Аутори
Grgurić-Šipka, SanjaVilaplana, RA
Perez, JM
Fuertes, MA
Alonso, C
Alvarez, Y
Sabo, Tibor
Gonzalez-Vilchez, F
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
The new potential antitumour soluble drug K[Ru(eddp)Cl-2].3H(2)O, (eddp = ethylenediamine-N,N'-di-3-propionate) has been isolated and characterized. The analysis of the interaction of this complex with pBR322 plasmid DNA by circular dichroism, spectroscopy shows that the ruthenium complex initially induces alteration of both CD positive and negative features resembling those previously observed for monofunctional platinum complexes. Further addition of drug at r(i) higher than 0.50 suggests appreciable conformational alterations of typical secondary structure of B-type DNA, implying loss of DNA helicity and unwinding of the double helix. The results reported herein about the binding of K[Ru(eddp)Cl-2] to the named plasmid performed by electrophoresis indicate that the Ru(III) center preferentially forms initial monofunctional adducts with this plasmid. In addition, the DNA binding data suggest that the plasmid is cleaved by K[Ru(eddp)Cl-2] in the presence of physiological concentration...s of ascorbate. These results support the hypothesis that reactive Ru(II) species may be formed from Ru(III) upon incubation with a reductant agent such as ascorbate. The testing of the cytotoxic activity of this complex against several human cancer cell lines evidenced that K[Ru(eddp)Cl-2] complex had a remarkable and selective antiproliferative effect against the cervix carcinoma HeLa and colon adenocarcinoma HT-29, behaving in these two cases as an antineoplastic drug. (C) 2003 Elsevier Inc. All rights reserved.
Кључне речи:
ruthenium complexes / circular dichroism / cytotoxicity / electrophoresis / ascorbateИзвор:
Journal of Inorganic Biochemistry, 2003, 97, 2, 215-220Издавач:
- Elsevier Science Inc, New York
DOI: 10.1016/S0162-0134(03)00281-2
ISSN: 0162-0134
PubMed: 14512200
WoS: 000185860600005
Scopus: 2-s2.0-0141739696
Колекције
Институција/група
Hemijski fakultet / Faculty of ChemistryTY - JOUR AU - Grgurić-Šipka, Sanja AU - Vilaplana, RA AU - Perez, JM AU - Fuertes, MA AU - Alonso, C AU - Alvarez, Y AU - Sabo, Tibor AU - Gonzalez-Vilchez, F PY - 2003 UR - https://cherry.chem.bg.ac.rs/handle/123456789/154 AB - The new potential antitumour soluble drug K[Ru(eddp)Cl-2].3H(2)O, (eddp = ethylenediamine-N,N'-di-3-propionate) has been isolated and characterized. The analysis of the interaction of this complex with pBR322 plasmid DNA by circular dichroism, spectroscopy shows that the ruthenium complex initially induces alteration of both CD positive and negative features resembling those previously observed for monofunctional platinum complexes. Further addition of drug at r(i) higher than 0.50 suggests appreciable conformational alterations of typical secondary structure of B-type DNA, implying loss of DNA helicity and unwinding of the double helix. The results reported herein about the binding of K[Ru(eddp)Cl-2] to the named plasmid performed by electrophoresis indicate that the Ru(III) center preferentially forms initial monofunctional adducts with this plasmid. In addition, the DNA binding data suggest that the plasmid is cleaved by K[Ru(eddp)Cl-2] in the presence of physiological concentrations of ascorbate. These results support the hypothesis that reactive Ru(II) species may be formed from Ru(III) upon incubation with a reductant agent such as ascorbate. The testing of the cytotoxic activity of this complex against several human cancer cell lines evidenced that K[Ru(eddp)Cl-2] complex had a remarkable and selective antiproliferative effect against the cervix carcinoma HeLa and colon adenocarcinoma HT-29, behaving in these two cases as an antineoplastic drug. (C) 2003 Elsevier Inc. All rights reserved. PB - Elsevier Science Inc, New York T2 - Journal of Inorganic Biochemistry T1 - Synthesis, characterization, interaction with DNA and cytotoxicity of the new potential antitumour drug cis-K[Ru(eddp)Cl-2] VL - 97 IS - 2 SP - 215 EP - 220 DO - 10.1016/S0162-0134(03)00281-2 ER -
@article{ author = "Grgurić-Šipka, Sanja and Vilaplana, RA and Perez, JM and Fuertes, MA and Alonso, C and Alvarez, Y and Sabo, Tibor and Gonzalez-Vilchez, F", year = "2003", abstract = "The new potential antitumour soluble drug K[Ru(eddp)Cl-2].3H(2)O, (eddp = ethylenediamine-N,N'-di-3-propionate) has been isolated and characterized. The analysis of the interaction of this complex with pBR322 plasmid DNA by circular dichroism, spectroscopy shows that the ruthenium complex initially induces alteration of both CD positive and negative features resembling those previously observed for monofunctional platinum complexes. Further addition of drug at r(i) higher than 0.50 suggests appreciable conformational alterations of typical secondary structure of B-type DNA, implying loss of DNA helicity and unwinding of the double helix. The results reported herein about the binding of K[Ru(eddp)Cl-2] to the named plasmid performed by electrophoresis indicate that the Ru(III) center preferentially forms initial monofunctional adducts with this plasmid. In addition, the DNA binding data suggest that the plasmid is cleaved by K[Ru(eddp)Cl-2] in the presence of physiological concentrations of ascorbate. These results support the hypothesis that reactive Ru(II) species may be formed from Ru(III) upon incubation with a reductant agent such as ascorbate. The testing of the cytotoxic activity of this complex against several human cancer cell lines evidenced that K[Ru(eddp)Cl-2] complex had a remarkable and selective antiproliferative effect against the cervix carcinoma HeLa and colon adenocarcinoma HT-29, behaving in these two cases as an antineoplastic drug. (C) 2003 Elsevier Inc. All rights reserved.", publisher = "Elsevier Science Inc, New York", journal = "Journal of Inorganic Biochemistry", title = "Synthesis, characterization, interaction with DNA and cytotoxicity of the new potential antitumour drug cis-K[Ru(eddp)Cl-2]", volume = "97", number = "2", pages = "215-220", doi = "10.1016/S0162-0134(03)00281-2" }
Grgurić-Šipka, S., Vilaplana, R., Perez, J., Fuertes, M., Alonso, C., Alvarez, Y., Sabo, T.,& Gonzalez-Vilchez, F.. (2003). Synthesis, characterization, interaction with DNA and cytotoxicity of the new potential antitumour drug cis-K[Ru(eddp)Cl-2]. in Journal of Inorganic Biochemistry Elsevier Science Inc, New York., 97(2), 215-220. https://doi.org/10.1016/S0162-0134(03)00281-2
Grgurić-Šipka S, Vilaplana R, Perez J, Fuertes M, Alonso C, Alvarez Y, Sabo T, Gonzalez-Vilchez F. Synthesis, characterization, interaction with DNA and cytotoxicity of the new potential antitumour drug cis-K[Ru(eddp)Cl-2]. in Journal of Inorganic Biochemistry. 2003;97(2):215-220. doi:10.1016/S0162-0134(03)00281-2 .
Grgurić-Šipka, Sanja, Vilaplana, RA, Perez, JM, Fuertes, MA, Alonso, C, Alvarez, Y, Sabo, Tibor, Gonzalez-Vilchez, F, "Synthesis, characterization, interaction with DNA and cytotoxicity of the new potential antitumour drug cis-K[Ru(eddp)Cl-2]" in Journal of Inorganic Biochemistry, 97, no. 2 (2003):215-220, https://doi.org/10.1016/S0162-0134(03)00281-2 . .